Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | An update on the ‘Watch’ registry: clonoSEQ® MRD monitoring in B-cell malignancies

Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, presents results from the interim analysis of the ‘Watch’ Registry (NCT04545333), a multicenter observational study investigating the use of measurable residual disease (MRD) measurement with Clonoseq® in clinical practice for B-cell malignancies. Dr Patel highlights that the use of MRD in clinical practice varied among diseases, and was commonly used to assess prognosis in chronic lymphocytic leukemia (CLL), and guide treatment decisions in acute lymphoblastic leukemia (ALL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

BeiGene: Consultancy; Epizyme: Consultancy, Research Funding; Curis, Inc: Research Funding; Fate Therapeutics: Research Funding; Genetech/Roche: Consultancy, Research Funding, Speakers Bureau; Caribou Biosciences: Consultancy; Celgene: Consultancy, Research Funding, Speakers Bureau; CRISPR Therapeutics: Research Funding; ADC Therapeutics: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Aptevo Therapeutics: Research Funding; AstraZeneca: Consultancy, Research Funding, Speakers Bureau; MEI Pharma: Consultancy, Research Funding; Kite pharma: Consultancy, Research Funding, Speakers Bureau; Loxo Oncology: Consultancy, Research Funding; Morphosys: Consultancy; Nurix: Research Funding; Pharmacyclics/Janssen: Consultancy, Research Funding, Speakers Bureau; Sunesis Pharmaceuticals: Research Funding; TG Therapeutics: Consultancy, Speakers Bureau; Trillium Therapuetics/Pfizer: Consultancy, Research Funding; Velos Bio: Research Funding; Xencor: Consultancy, Research Funding; Abbvie: Consultancy; Adaptive Biotechnologies: Research Funding.